http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 01 May 2026 07:18:37 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+PT+Change/DBV+Technologies+S.A+%28DBVT%29+PT+Raised+to+%2455+at+Citizens/26411924.html Citizens analyst Jonathan Wolleben raised the price target on DBV Technologies S.A (NASDAQ: DBVT) to $55.00 (from $47.00) while maintaining a Market Outperform rating. http://www.streetinsider.com/Analyst+PT+Change/DBV+Technologies+S.A+%28DBVT%29+PT+Raised+to+%2455+at+Citizens/26411924.html Fri, 01 May 2026 07:18:37 -0400 DBVT http://www.streetinsider.com/Earnings/DBV+Technologies+%28DBVT%29+Misses+Q1+EPS+by+11c/26410108.html <p>DBV Technologies (NASDAQ: DBVT) reported Q1 EPS of ($0.11).</p><p>For earnings history and earnings-related data on DBV Technologies (DBVT) <a href="http://www.streetinsider.com/ec_earnings.php?q=DBVT">click here</a>.</p> http://www.streetinsider.com/Earnings/DBV+Technologies+%28DBVT%29+Misses+Q1+EPS+by+11c/26410108.html Thu, 30 Apr 2026 17:13:59 -0400 DBVT http://www.streetinsider.com/SEC+Filings/Form++3++++++++++DBV+Technologies+S.A.+++++For%3A+Oct+30++Filed+by%3A+Lee+Philina/26325752.html si-local-file:///var/storage/secattach/20260416/26325752.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++DBV+Technologies+S.A.+++++For%3A+Oct+30++Filed+by%3A+Lee+Philina/26325752.html Thu, 16 Apr 2026 16:52:00 -0400 DBV DBVT O.26593910 http://www.streetinsider.com/SEC+Filings/Form++3++++++++++DBV+Technologies+S.A.+++++For%3A+Oct+30++Filed+by%3A+Lee+Philina/26325752.html si-local-file:///var/storage/secattach/20260416/26325752.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++DBV+Technologies+S.A.+++++For%3A+Oct+30++Filed+by%3A+Lee+Philina/26325752.html Thu, 16 Apr 2026 16:52:00 -0400 DBV DBVT O.26593910 http://www.streetinsider.com/SEC+Filings/Form++3++++++++++DBV+Technologies+S.A.+++++For%3A+Oct+30++Filed+by%3A+Lee+Philina/26325752.html si-local-file:///var/storage/secattach/20260416/26325752.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++DBV+Technologies+S.A.+++++For%3A+Oct+30++Filed+by%3A+Lee+Philina/26325752.html Thu, 16 Apr 2026 16:52:00 -0400 DBV DBVT O.26593910 http://www.streetinsider.com/Intl+Ratings/DBV+Technologies+S.A+%28DBV%3AFP%29+%28DBVT%29+PT+Lowered+to+EUR1.01+at+Goldman+Sachs/26292226.html Goldman Sachs analyst Rajan Sharma lowered the price target on DBV Technologies S.A (DBV:FP) (NASDAQ: DBVT) to EUR1.01 (from EUR1.37) while maintaining a Sell rating. http://www.streetinsider.com/Intl+Ratings/DBV+Technologies+S.A+%28DBV%3AFP%29+%28DBVT%29+PT+Lowered+to+EUR1.01+at+Goldman+Sachs/26292226.html Thu, 09 Apr 2026 07:51:29 -0400 DBVT http://www.streetinsider.com/Intl+Ratings/DBV+Technologies+S.A+%28DBV%3AFP%29+%28DBVT%29+PT+Lowered+to+EUR1.01+at+Goldman+Sachs/26292226.html Goldman Sachs analyst Rajan Sharma lowered the price target on DBV Technologies S.A (DBV:FP) (NASDAQ: DBVT) to EUR1.01 (from EUR1.37) while maintaining a Sell rating. http://www.streetinsider.com/Intl+Ratings/DBV+Technologies+S.A+%28DBV%3AFP%29+%28DBVT%29+PT+Lowered+to+EUR1.01+at+Goldman+Sachs/26292226.html Thu, 09 Apr 2026 07:51:29 -0400 DBVT http://www.streetinsider.com/Analyst+PT+Change/DBV+Technologies+S.A+%28DBV%3AFP%29+%28DBVT%29+PT+Lowered+to+EUR1.01+at+Goldman+Sachs/26292226.html Goldman Sachs analyst Rajan Sharma lowered the price target on DBV Technologies S.A (DBV:FP) (NASDAQ: DBVT) to EUR1.01 (from EUR1.37) while maintaining a Sell rating. http://www.streetinsider.com/Analyst+PT+Change/DBV+Technologies+S.A+%28DBV%3AFP%29+%28DBVT%29+PT+Lowered+to+EUR1.01+at+Goldman+Sachs/26292226.html Thu, 09 Apr 2026 07:51:29 -0400 DBVT http://www.streetinsider.com/Analyst+PT+Change/DBV+Technologies+S.A+%28DBV%3AFP%29+%28DBVT%29+PT+Lowered+to+EUR1.01+at+Goldman+Sachs/26292226.html Goldman Sachs analyst Rajan Sharma lowered the price target on DBV Technologies S.A (DBV:FP) (NASDAQ: DBVT) to EUR1.01 (from EUR1.37) while maintaining a Sell rating. http://www.streetinsider.com/Analyst+PT+Change/DBV+Technologies+S.A+%28DBV%3AFP%29+%28DBVT%29+PT+Lowered+to+EUR1.01+at+Goldman+Sachs/26292226.html Thu, 09 Apr 2026 07:51:29 -0400 DBVT http://www.streetinsider.com/Analyst+PT+Change/DBV+Technologies+S.A+%28DBVT%29+PT+Lowered+to+%245.81+at+Goldman+Sachs/26291281.html Goldman Sachs analyst Rajan Sharma lowered the price target on DBV Technologies S.A (NASDAQ: DBVT) to $5.81 (from $7.94) while maintaining a Sell rating. http://www.streetinsider.com/Analyst+PT+Change/DBV+Technologies+S.A+%28DBVT%29+PT+Lowered+to+%245.81+at+Goldman+Sachs/26291281.html Thu, 09 Apr 2026 05:56:55 -0400 DBVT http://www.streetinsider.com/Press+Releases/Information+Regarding+the+Total+Number+of+Voting+Rights+and+Total+Number+of+Shares+of+the+Company+as+of+March+31%2C+2026/26267411.html <p align="center"><b>Information Regarding the Total Number of Voting Rights and </b><br/><b>Total Number of Shares of the Company as of March 31, 2026</b></p> <p align="center">(Article 223-16 of the General Regulations of the <i>Autorité des Marchés Financiers</i>)</p> <p align="left">Market : NYSE Euronext Paris <br/>ISIN Code: FR 0010417345</p> <table align="center" style="border-collapse: collapse; width:482pt; border-collapse:collapse ;"><tr><td style="width:174.8px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; text-align: center ; vertical-align: middle; "> <br/><br/><b>Date</b><br/><br/> </td><td style="width:161.14px;;text-align: center ; vertical-align: middle; border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid http://www.streetinsider.com/Press+Releases/Information+Regarding+the+Total+Number+of+Voting+Rights+and+Total+Number+of+Shares+of+the+Company+as+of+March+31%2C+2026/26267411.html Thu, 02 Apr 2026 16:30:00 -0400 DBV DBVT O.26593910 http://www.streetinsider.com/Press+Releases/Information+Regarding+the+Total+Number+of+Voting+Rights+and+Total+Number+of+Shares+of+the+Company+as+of+March+31%2C+2026/26267411.html <p align="center"><b>Information Regarding the Total Number of Voting Rights and </b><br/><b>Total Number of Shares of the Company as of March 31, 2026</b></p> <p align="center">(Article 223-16 of the General Regulations of the <i>Autorité des Marchés Financiers</i>)</p> <p align="left">Market : NYSE Euronext Paris <br/>ISIN Code: FR 0010417345</p> <table align="center" style="border-collapse: collapse; width:482pt; border-collapse:collapse ;"><tr><td style="width:174.8px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; text-align: center ; vertical-align: middle; "> <br/><br/><b>Date</b><br/><br/> </td><td style="width:161.14px;;text-align: center ; vertical-align: middle; border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid http://www.streetinsider.com/Press+Releases/Information+Regarding+the+Total+Number+of+Voting+Rights+and+Total+Number+of+Shares+of+the+Company+as+of+March+31%2C+2026/26267411.html Thu, 02 Apr 2026 16:30:00 -0400 DBV DBVT O.26593910 http://www.streetinsider.com/Press+Releases/Information+Regarding+the+Total+Number+of+Voting+Rights+and+Total+Number+of+Shares+of+the+Company+as+of+March+31%2C+2026/26267411.html <p align="center"><b>Information Regarding the Total Number of Voting Rights and </b><br/><b>Total Number of Shares of the Company as of March 31, 2026</b></p> <p align="center">(Article 223-16 of the General Regulations of the <i>Autorité des Marchés Financiers</i>)</p> <p align="left">Market : NYSE Euronext Paris <br/>ISIN Code: FR 0010417345</p> <table align="center" style="border-collapse: collapse; width:482pt; border-collapse:collapse ;"><tr><td style="width:174.8px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; text-align: center ; vertical-align: middle; "> <br/><br/><b>Date</b><br/><br/> </td><td style="width:161.14px;;text-align: center ; vertical-align: middle; border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid http://www.streetinsider.com/Press+Releases/Information+Regarding+the+Total+Number+of+Voting+Rights+and+Total+Number+of+Shares+of+the+Company+as+of+March+31%2C+2026/26267411.html Thu, 02 Apr 2026 16:30:00 -0400 DBV DBVT O.26593910 http://www.streetinsider.com/Globe+Newswire/Information+Regarding+the+Total+Number+of+Voting+Rights+and+Total+Number+of+Shares+of+the+Company+as+of+March+31%2C+2026/26267411.html <p align="center"><b>Information Regarding the Total Number of Voting Rights and </b><br/><b>Total Number of Shares of the Company as of March 31, 2026</b></p> <p align="center">(Article 223-16 of the General Regulations of the <i>Autorité des Marchés Financiers</i>)</p> <p align="left">Market : NYSE Euronext Paris <br/>ISIN Code: FR 0010417345</p> <table align="center" style="border-collapse: collapse; width:482pt; border-collapse:collapse ;"><tr><td style="width:174.8px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; text-align: center ; vertical-align: middle; "> <br/><br/><b>Date</b><br/><br/> </td><td style="width:161.14px;;text-align: center ; vertical-align: middle; border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid http://www.streetinsider.com/Globe+Newswire/Information+Regarding+the+Total+Number+of+Voting+Rights+and+Total+Number+of+Shares+of+the+Company+as+of+March+31%2C+2026/26267411.html Thu, 02 Apr 2026 16:30:00 -0400 DBV DBVT O.26593910 http://www.streetinsider.com/Globe+Newswire/Information+Regarding+the+Total+Number+of+Voting+Rights+and+Total+Number+of+Shares+of+the+Company+as+of+March+31%2C+2026/26267411.html <p align="center"><b>Information Regarding the Total Number of Voting Rights and </b><br/><b>Total Number of Shares of the Company as of March 31, 2026</b></p> <p align="center">(Article 223-16 of the General Regulations of the <i>Autorité des Marchés Financiers</i>)</p> <p align="left">Market : NYSE Euronext Paris <br/>ISIN Code: FR 0010417345</p> <table align="center" style="border-collapse: collapse; width:482pt; border-collapse:collapse ;"><tr><td style="width:174.8px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; text-align: center ; vertical-align: middle; "> <br/><br/><b>Date</b><br/><br/> </td><td style="width:161.14px;;text-align: center ; vertical-align: middle; border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid http://www.streetinsider.com/Globe+Newswire/Information+Regarding+the+Total+Number+of+Voting+Rights+and+Total+Number+of+Shares+of+the+Company+as+of+March+31%2C+2026/26267411.html Thu, 02 Apr 2026 16:30:00 -0400 DBV DBVT O.26593910 http://www.streetinsider.com/Globe+Newswire/Information+Regarding+the+Total+Number+of+Voting+Rights+and+Total+Number+of+Shares+of+the+Company+as+of+March+31%2C+2026/26267411.html <p align="center"><b>Information Regarding the Total Number of Voting Rights and </b><br/><b>Total Number of Shares of the Company as of March 31, 2026</b></p> <p align="center">(Article 223-16 of the General Regulations of the <i>Autorité des Marchés Financiers</i>)</p> <p align="left">Market : NYSE Euronext Paris <br/>ISIN Code: FR 0010417345</p> <table align="center" style="border-collapse: collapse; width:482pt; border-collapse:collapse ;"><tr><td style="width:174.8px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; text-align: center ; vertical-align: middle; "> <br/><br/><b>Date</b><br/><br/> </td><td style="width:161.14px;;text-align: center ; vertical-align: middle; border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid http://www.streetinsider.com/Globe+Newswire/Information+Regarding+the+Total+Number+of+Voting+Rights+and+Total+Number+of+Shares+of+the+Company+as+of+March+31%2C+2026/26267411.html Thu, 02 Apr 2026 16:30:00 -0400 DBV DBVT O.26593910 http://www.streetinsider.com/Analyst+Comments/DBV+Technologies+S.A+%28DBVT%29+Reiterated+at+Overweight+by+Cantor+Fitzgerald+/26238271.html <p>Cantor Fitzgerald analyst Kristen Kluska reiterated an Overweight rating and $48.00 price target on DBV Technologies S.A (NASDAQ: DBVT).</p><p>The analyst commented, "Seeing how many physicians at least tried Palforzia suggests to us there is an eagerness for this population to be treated. The core concerns around Palforzia, around cumbersome scheduling/too many office visits, won't be relevant for VIASKIN, as this is an at-home administered patch. Reimbursement is something we will have to see play out. The reasons behind the lack of greater Xolair use also don't apply to VIASKIN, as this patch has shown both desensitization potential and doesn't require http://www.streetinsider.com/Analyst+Comments/DBV+Technologies+S.A+%28DBVT%29+Reiterated+at+Overweight+by+Cantor+Fitzgerald+/26238271.html Mon, 30 Mar 2026 09:33:42 -0400 DBVT http://www.streetinsider.com/Analyst+Comments/DBV+Technologies+S.A+%28DBVT%29+Reiterated+at+Overweight+by+Cantor+Fitzgerald%3A+More+Upside/26228034.html <p>Cantor Fitzgerald analyst Kristen Kluska reiterated an Overweight rating and $48.00 price target on DBV Technologies S.A (NASDAQ: DBVT).</p><p>The analyst commented, "While DBV's stock has performed well over the last 18 months, we still believe there is much more upside to unlock. Our model assumes unadjusted peak sales of $1.1B for the 4-7 year old group, and $832M for the 1-3 year old group. Based on this we estimate that the market is currently ascribing a PoS of ~40-45%, a big disconnect in light of the derisking Phase 3 data. Even if one has a higher conviction on an approval, http://www.streetinsider.com/Analyst+Comments/DBV+Technologies+S.A+%28DBVT%29+Reiterated+at+Overweight+by+Cantor+Fitzgerald%3A+More+Upside/26228034.html Fri, 27 Mar 2026 07:24:39 -0400 DBVT http://www.streetinsider.com/Analyst+PT+Change/DBV+Technologies+S.A+%28DBVT%29+PT+Raised+to+%2447+at+Citizens%3B+Shares+Recommended/26226939.html <p>Citizens analyst Jonathan Wolleben raised the price target on DBV Technologies S.A (NASDAQ: DBVT) to $47.00 (from $45.00) while maintaining a Market Outperform rating.</p><p>The analyst commented, "Viaskin Peanut hit convincingly in the Phase 3 VITESSE trial in 4-7 year olds back in December and we think approval next year is likely (90% POS). DBVT presented the data for the first time at the recent AAAAI meeting where allergists were particularly excited about Viaskin Peanut's immunomodulator mechanism of action, clean safety, and practical approach, which all point to the ability to treat young patients – a growing theme in the allergist http://www.streetinsider.com/Analyst+PT+Change/DBV+Technologies+S.A+%28DBVT%29+PT+Raised+to+%2447+at+Citizens%3B+Shares+Recommended/26226939.html Fri, 27 Mar 2026 04:03:06 -0400 DBVT http://www.streetinsider.com/Analyst+Comments/DBV+Technologies+S.A+%28DBVT%29+PT+Raised+to+%2447+at+Citizens%3B+Shares+Recommended/26226939.html <p>Citizens analyst Jonathan Wolleben raised the price target on DBV Technologies S.A (NASDAQ: DBVT) to $47.00 (from $45.00) while maintaining a Market Outperform rating.</p><p>The analyst commented, "Viaskin Peanut hit convincingly in the Phase 3 VITESSE trial in 4-7 year olds back in December and we think approval next year is likely (90% POS). DBVT presented the data for the first time at the recent AAAAI meeting where allergists were particularly excited about Viaskin Peanut's immunomodulator mechanism of action, clean safety, and practical approach, which all point to the ability to treat young patients – a growing theme in the allergist http://www.streetinsider.com/Analyst+Comments/DBV+Technologies+S.A+%28DBVT%29+PT+Raised+to+%2447+at+Citizens%3B+Shares+Recommended/26226939.html Fri, 27 Mar 2026 04:03:06 -0400 DBVT http://www.streetinsider.com/Press+Releases/DBV+Technologies+Announces+Filing+of+2025+Annual+Report+on+Form+10-K+and+Universal+Registration+Document/26225809.html <p align="right">Châtillon, France, March 26, 2026 </p> <p align="justify"><b>DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document</b></p> <p align="justify">DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company (the “Company”), today announced the filing, for the year ended December 31, 2025, of its Annual Report on Form 10-K with the U.S. Securities and Exchange Commission (“SEC”) and its Universal Registration Document (“ 2025 URD”) with the French market authority, “<i>Autorité des Marchés Financiers</i>” (“AMF”).</p> <p align="justify">In compliance with French law, the following information are included http://www.streetinsider.com/Press+Releases/DBV+Technologies+Announces+Filing+of+2025+Annual+Report+on+Form+10-K+and+Universal+Registration+Document/26225809.html Thu, 26 Mar 2026 17:19:00 -0400 A.26800952 DBV DBVT O.00711722 O.26593910 http://www.streetinsider.com/Press+Releases/DBV+Technologies+Announces+Filing+of+2025+Annual+Report+on+Form+10-K+and+Universal+Registration+Document/26225809.html <p align="right">Châtillon, France, March 26, 2026 </p> <p align="justify"><b>DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document</b></p> <p align="justify">DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company (the “Company”), today announced the filing, for the year ended December 31, 2025, of its Annual Report on Form 10-K with the U.S. Securities and Exchange Commission (“SEC”) and its Universal Registration Document (“ 2025 URD”) with the French market authority, “<i>Autorité des Marchés Financiers</i>” (“AMF”).</p> <p align="justify">In compliance with French law, the following information are included http://www.streetinsider.com/Press+Releases/DBV+Technologies+Announces+Filing+of+2025+Annual+Report+on+Form+10-K+and+Universal+Registration+Document/26225809.html Thu, 26 Mar 2026 17:19:00 -0400 A.26800952 DBV DBVT O.00711722 O.26593910 http://www.streetinsider.com/Press+Releases/DBV+Technologies+Announces+Filing+of+2025+Annual+Report+on+Form+10-K+and+Universal+Registration+Document/26225809.html <p align="right">Châtillon, France, March 26, 2026 </p> <p align="justify"><b>DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document</b></p> <p align="justify">DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company (the “Company”), today announced the filing, for the year ended December 31, 2025, of its Annual Report on Form 10-K with the U.S. Securities and Exchange Commission (“SEC”) and its Universal Registration Document (“ 2025 URD”) with the French market authority, “<i>Autorité des Marchés Financiers</i>” (“AMF”).</p> <p align="justify">In compliance with French law, the following information are included http://www.streetinsider.com/Press+Releases/DBV+Technologies+Announces+Filing+of+2025+Annual+Report+on+Form+10-K+and+Universal+Registration+Document/26225809.html Thu, 26 Mar 2026 17:19:00 -0400 A.26800952 DBV DBVT O.00711722 O.26593910 http://www.streetinsider.com/Press+Releases/DBV+Technologies+Announces+Filing+of+2025+Annual+Report+on+Form+10-K+and+Universal+Registration+Document/26225809.html <p align="right">Châtillon, France, March 26, 2026 </p> <p align="justify"><b>DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document</b></p> <p align="justify">DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company (the “Company”), today announced the filing, for the year ended December 31, 2025, of its Annual Report on Form 10-K with the U.S. Securities and Exchange Commission (“SEC”) and its Universal Registration Document (“ 2025 URD”) with the French market authority, “<i>Autorité des Marchés Financiers</i>” (“AMF”).</p> <p align="justify">In compliance with French law, the following information are included http://www.streetinsider.com/Press+Releases/DBV+Technologies+Announces+Filing+of+2025+Annual+Report+on+Form+10-K+and+Universal+Registration+Document/26225809.html Thu, 26 Mar 2026 17:19:00 -0400 A.26800952 DBV DBVT O.00711722 O.26593910 http://www.streetinsider.com/Press+Releases/DBV+Technologies+Announces+Filing+of+2025+Annual+Report+on+Form+10-K+and+Universal+Registration+Document/26225809.html <p align="right">Châtillon, France, March 26, 2026 </p> <p align="justify"><b>DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document</b></p> <p align="justify">DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company (the “Company”), today announced the filing, for the year ended December 31, 2025, of its Annual Report on Form 10-K with the U.S. Securities and Exchange Commission (“SEC”) and its Universal Registration Document (“ 2025 URD”) with the French market authority, “<i>Autorité des Marchés Financiers</i>” (“AMF”).</p> <p align="justify">In compliance with French law, the following information are included http://www.streetinsider.com/Press+Releases/DBV+Technologies+Announces+Filing+of+2025+Annual+Report+on+Form+10-K+and+Universal+Registration+Document/26225809.html Thu, 26 Mar 2026 17:19:00 -0400 A.26800952 DBV DBVT O.00711722 O.26593910